Comprehensive Genomic Profiling Alters Clinical Diagnoses in a Significant Fraction of Tumors Suspicious of Sarcoma
Ingegerd Öfverholm*,Karin Wallander*,Cecilia Haglund,Venkatesh Chellappa,Johan Wejde,Anna Gellerbring,Valtteri Wirta,Annick Renevey,Eva Caceres,Panagiotis Tsagkozis,Markus Mayrhofer,Andri Papakonstantinou,Christina Linder-Stragliotto,Robert Bränström,Olle Larsson,Johan Lindberg,Yingbo Lin,Felix Haglund de Flon
DOI: https://doi.org/10.1158/1078-0432.ccr-24-0384
IF: 13.801
2024-04-05
Clinical Cancer Research
Abstract:Purpose: Tumor classification is a key component in personalized cancer care. For soft tissue and bone tumors, this classification is currently based primarily on morphology assessment and immunohistochemical staining. However, these standard-of-care methods can pose challenges for pathologists. We therefore assessed how whole-genome and whole-transcriptome sequencing (WGTS) impacted tumor classification and clinical management when interpreted together with histomorphology. Experimental design: We prospectively evaluated WGTS in routine diagnostics of 200 soft tissue and bone tumors suspicious for malignancy, including DNA and RNA isolation from the tumor, and DNA isolation from a peripheral blood sample or any non-tumor tissue. Results: Based on specific genomic alterations or absence of presumed findings, WGTS resulted in reclassification of 7% (13/197) of the histopathological diagnoses. Four cases were downgraded from low-grade sarcomas to benign lesions, and two cases were reclassified as metastatic malignant melanomas. Fusion genes associated with specific tumor entities were found in 30 samples. For malignant soft tissue and bone tumors, we identified treatment relevant variants in 15% of cases. Germline pathogenic variants associated to a hereditary cancer syndrome were found in 22 participants (11%). Conclusion: We conclude that WGTS provides an important dimension of data which aids in the classification of soft tissue and bone tumors, correcting a significant fraction of clinical diagnoses, and identifies molecular targets relevant for precision medicine. However, genetic findings need to be evaluated in their morphopathological context, just as germline findings need to be evaluated in the context of patient phenotype and family history.
oncology